Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project

• Published in: BMC psychiatry Vol. 23; no. 1; p. 473
• Main Authors: Hashimoto, Naoki, Yasui-Furukori, Norio, Hasegawa, Naomi, Ishikawa, Shuhei, Hori, Hikaru, Iida, Hitoshi, Ichihashi, Kayo, Miura, Kenichiro, Matsumoto, Junya, Numata, Shusuke, Kodaka, Fumitoshi, Furihata, Ryuji, Ohi, Kazutaka, Ogasawara, Kazuyoshi, Iga, Jun-Ichi, Muraoka, Hiroyuki, Komatsu, Hiroshi, Takeshima, Masahiro, Atake, Kiyokazu, Kido, Mikio, Nakamura, Toshinori, Kishimoto, Taishiro, Hishimoto, Akitoyo, Onitsuka, Toshiaki, Okada, Tsuyoshi, Ochi, Shinichiro, Nagasawa, Tatsuya, Makinodan, Manabu, Yamada, Hiroki, Tsuboi, Takashi, Yamada, Hisashi, Inada, Ken, Watanabe, Koichiro, Hashimoto, Ryota
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 28.06.2023; BioMed Central; BMC
• Subjects: Antidepressants; Antipsychotics; Chi-square test; Depressive Disorder, Major - drug therapy; Drug dosages; Drug therapy; Drugs; Education; Educational Status; Hospitalization; Humans; International standards; Major depressive disorder; Mental depression; Mental disorders; Monotherapy; Patient Discharge; Patients; Polypharmacy; Prescribing; Prescription drugs; Psychiatrists; Psychiatry; Psychotropic drugs; Psychotropics; Schizophrenia; Schizophrenia - drug therapy; Tranquilizers; Japan; Antipsychotics; Polypharmacy; Psychotropics; Antidepressants; Monotherapy
• ISSN: 1471-244X; 1471-244X
• DOI: 10.1186/s12888-023-04908-4

Polypharmacy of additional psychotropics alongside the main treatment drug (antipsychotics in schizophrenia and antidepressants in major depressive disorder) is common in Japan. Our goal is to align psychotropic prescription in Japan with international standards, while reducing the differences between facilities. To achieve this goal, we aimed to compare prescriptions at the time of hospital admission and discharge. Data on prescriptions at admission and discharge from 2016 to 2020 were collected. We divided the patients into four groups: (1) mono_mono group, monotherapy of the main drug at admission and discharge; (2) mono_poly group, monotherapy at admission and polypharmacy at discharge; (3) poly_poly group, polypharmacy at admission and discharge; and (4) poly_mono group, polypharmacy at admission and monotherapy at discharge. We compared the changes in dosage and number of psychotropics among the four groups. For both schizophrenia and major depressive disorder, the patients who received monotherapy with the main drug at admission were likely to receive main drug monotherapy at discharge and vice versa. For schizophrenia, the polypharmacy was prescribed more often in the mono_poly group than that in the mono_mono group. The prescription was not changed at all for more than 10% of the patients. It is critical to avoid a polypharmacy regimen to ensure that guideline-compliant treatment is provided. We expect higher rates of monotherapy with the main drug after the EGUIDE lectures. The study protocol was registered in the University Hospital Medical Information Network Registry (UMIN000022645).